Day 1 – Physician Meet – Scientific Program

Thursday, October 26th 2023

Basic Hematopoietic Stem Cell Transplant

08.00 AM – 09.00 AM

Session 1
Indications of HCT in Various Diagnosis

Chairman: Bambang Sudarmanto, MD (Semarang)

08.00 AM – 08.20 AM

Indications and Results of HCT in Leukemia
Damai Santosa, MD, Ph.D (Semarang)

08.20 AM – 08.40 AM

Indications and Results of HCT in MM
Prof. Dr. dr. S. Ugroseno Yudho Bintoro, Sp.PD, K-HOM (Surabaya)

08.40 AM – 09.00 AM Discussion
09.00 AM – 10.00 AM

Session 2
Fundamentals of Hematopoietic Stem Cell Transplant

Chairman : Mika L. Tobing, MD (Semarang)

09.00 AM – 09.20 AM

Biological Properties of HSC: Scientific Basis for HSCT
T. Djumhana A., MD, Ph.D (Jakarta)

09.20 AM – 09.40 AM

Criteria of Donor Choice. Matched Unrelated Donor vs Haploidentical Donor vs Cord Blood & Principles of HLA Typing for the Clinician
Nadia Ayu Mulansari, MD (Jakarta)

09.40 AM – 10.00 AM Discussion
09.40 AM – 10.00 AM Coffee Break
10.00 AM – 11.00 AM

Session 3
Technical Issue of HSCT

Chairman : Putu Niken Ayu Amrita, MD (Surabaya)

10.00 AM – 10.20 AM

Mobilization for Peripheral Blood Stem Cell Collecting
Daniel Rizky, MD (Semarang)

10.20 AM – 10.40 AM

Conditioning Regimens. Reduced Intensity vs Myeloablative
Alberto Musseti, MD (Barcelona)

10.40 AM – 11.00 AM Discussion
11.00 AM – 12.00 AM

Session 4
Complications after HSCT, Infection Control, and Blood Support

Chairman : Cosphiadi Irawan, MD, Ph.D (Jakarta)

11.00 AM – 11.20 AM

Early and Late Complications after HCT
Alberto Musseti, MD (Barcelona)

11.20 AM – 11.40 AM

Blood Support during HSCT
Dian Widyaningrum, MD (Semarang)

11.40 AM – 12.00 PM Discussion
12.00 AM – 01.00 PM

Industry Lunch Symposium

Chairman : Damai Santosa, MD, Ph.D (Semarang)

12.00 AM – 12.40 PM

Smart To Manage HSCT Patient with Invasive Fungal Infections
Alberto Musseti, MD (Barcelona)

12.40 PM – 01.00 PM Discussion
01.00 PM – 01.40 PM Update of Classical Hodgkin Lymphoma
01.00 PM – 01.20 PM

Real-world Outcomes of Brentuximab Vedotin in Relapsed/Refractory Classical Hodgkin lymphoma
Johan Kurnianda, MD (Yogyakarta)

01.20 PM – 01.40 PM Discussion
01.40 PM – 02.40 PM

Updates on CLL Management
Chairman : DBudi Setiawan, MD, Ph.D (Semarang)

01.40 PM – 02.00 PM

New Approach Treatment: Acalabrutinib Second Generation BTKi Update for Naive and R/R CLL patient with/without High-Risk Factor
Jeffry Beta Tenggara, MD (Jakarta)

02.00 PM – 02.20 PM

Role of Clinical & Molecular Laboratory in Chronic Lymphocytic Leukemia : Updates on International Guidelines and Building National Capacity
Christine Sugiarto, MD (Jakarta)

02.20 PM – 02.40 PM Discussion